

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00227 A1

(51) International Patent Classification⁷: **A61K 38/09,**
A61P 5/04

VOORTMAN, Gerrit [NL/NL]; Laan 1940-1945 No. 7,
NL-7231 GJ Warnsveld (NL).

(21) International Application Number: **PCT/EP00/05643**

(74) Agent: **HERMANS, F., G., M.**; P.O. Box 20, NL-5340
BH Oss (NL).

(22) International Filing Date: **19 June 2000 (19.06.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(81) Designated States (*national*): **AL, AU, BA, BB, BG, BR,**
CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP,
KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL,
RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU,
ZA.

(30) Priority Data:
99202027.1 **23 June 1999 (23.06.1999)** **EP**

(84) Designated States (*regional*): **ARIPO** patent (**GH, GM,**
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian**
patent (**AM, AZ, BY, KG, KZ, MD, RU, TJ, TM**), **European**
patent (**AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,**
IT, LU, MC, NL, PT, SE), **OAPI** patent (**BF, BJ, CF, CG,**
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **AKZO**
NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arn-
hem (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DE GREEF, Hen-**
rik, Johan, Matthieu, Maria [NL/NL]; Gruttersdijk 39,
NL-3514 BH Utrecht (NL). **MANNAERTS, Bernadette,**
Maria, Julia, Louise [NL/NL]; Acacialeaan 24, NL-5384
BB Heesch (NL). **ORLEMANS, Everardus, Otto,**
Maria [NL/NL]; Wolfespoor 12, NL-5343 XM Oss (NL).

Published:

— *With international search report.*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **GONADOTROPIN RELEASING HORMONE ANTAGONIST**

(57) Abstract: The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount dependent on the body weight of the patient. The method can be used in combination with administration of exogenous FSH in the treatment of women undergoing controlled ovarian super-ovulation.



WO 01/00227 A1

Gonadotropin releasing hormone antagonist

5 The present invention relates to the use of GnRH antagonists in controlled ovarian hyperstimulation (COH) as well as to a method to prevent premature LH surge. It also relates to a cartridge comprising said antagonist and a kit comprising said cartridge and FSH.

10 The glycoprotein hormones Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) are released from the pituitary gland under control of Gonadotropin Releasing Hormone (GnRH). They act on the ovary to stimulate steroid synthesis and secretion and thus play a central role in the reproductive cycle.

15 In the normal cycle, there is a mid-cycle surge in LH concentration which is followed by ovulation. The LH surge is a consequence of the raise in estrogen levels brought about by the endogenous secretion of LH and FSH. The estrogen is part of a positive feedback mechanism resulting in the elevated LH level.

20 GnRH analogues are useful for a variety of disorders in which immediate reversible suppression of the pituitary-gonadal axis is desired. This can in principle be achieved with GnRH agonists as well as with GnRH antagonists. In comparison to GnRH agonists, GnRH antagonists have the advantage of not inducing an initial release of gonadotropins (flare-up) and steroids before suppression.

25 Currently, GnRH agonists are clinically applied for the prevention of endogenous LH-surges during controlled ovarian hyperstimulation for Assisted Reproduction Techniques (ART). Specific disadvantages of GnRH agonists are the initial flare-up and the rather long period until pituitary suppression becomes effective. Usually, patients undergoing COH start only treatment with (recombinant) FSH after 2 to 3 weeks pretreatment with GnRH agonists.

30 Women treated for this purpose without GnRH analogues, all show attenuated LH rises irrespective of the treatment schedule used. Usually these rises occur prematurely due to a positive feedback of rising estradiol (E2)

produced by a cohort of relative small follicles. The exposure of non-mature follicles to high levels of LH leads to premature luteinisation of granulosa cells and hence to increased production of progesterone and decreased synthesis of E2. These changes lead to disrupted maturation and decreased fertilization and implantation rates. Success rates of COH cycles in which premature LH rises are detected, are reported to be low and often these cycles are canceled because the number and/or size of follicles is still too small.

GnRH antagonists by GnRH receptor competition provide an immediate inhibition of gonadotropin secretion, especially of LH. Thus, during COH by FSH, GnRH antagonist treatment is only required during the few days when there is an increased risk for a premature LH surge. It has been found that the GnRH antagonist dosage range is critical: too low a GnRH antagonist dosage leading to premature LH rises, while too high a GnRH antagonist dosage hampered follicular maturation. For the antagonist ganirelix for example a fixed amount being at least 0.125 mg but less than 1 mg and preferably about 0.25 mg was suggested (WO98/58657).

Surprisingly, however, it has now been found that there is no relationship between the implantation rate and level of LH (AUC), whereas there does exist a relationship between the GnRH antagonist levels (AUC) and the implantation rate. It has now been found that antagonist is to be administered in an amount depending on the body weight (BW).

The invention therefore relates to a pharmaceutical preparation comprising GnRH antagonist, while applying a dosage adjusted for body weight sufficient to prevent a premature LH surge and ensuring successful treatment outcome. Such preparation is useful in the treatment of women undergoing COH.

A preferred antagonist according to the present invention is ganirelix which has the following chemical name:

N-Acetyl-3-(2-naphtyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-N⁹,N¹⁰-diethyl-D-homoarginyl-L-leucin-N⁹,N¹⁰-diethyl-L-homoarginyl-L-propyl-D-alanylamide acetate. The abbreviated structure is [N-Ac-D-Na(2)¹,D-pClPhe²,D-Pal(3)³,D-hArg(Et₂)⁶,L-hArg(Et₂)⁸,D-Ala¹⁰-GnRH.

The GnRH antagonist ganirelix is disclosed in US patent No. 4,801,577 for nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists. This patent, which is fully incorporated herein by reference, describes the method for the preparation of these compounds. It is indicated that the compounds described therein can be used for the prevention of ovarian hyperstimulation. For human therapy a daily range is suggested for administration of the active ingredient between 0.001 and 5 mg/kg body weight, preferably between 0.01 and 1 mg/kg.

It has now been found that the optimal relationship between body weight and GnRH antagonist dosage can be defined (in micrograms) by the Formula: $(5.5 \cdot BW - 166) \pm 7\%$ (Formula I) wherein BW represents the body weight of the patient in kg.

The preparation is administered together with FSH during the days of ovarian stimulation when a premature LH rise may easily occur e.g. from day 5 of FSH administration onwards. The preparation in its proposed dosage range has the advantage of providing an immediate effect that prevents an LH surge and at the same time maximizes the chances of establishing pregnancy. Administration is usually stopped when sufficient follicles have matured and exogenous hCG/LH is given for induction of ovulation. The amount of hCG/LH usually amounts 5000-10000 IU. Alternatively, induction of ovulation can be performed by administration of a GnRH agonist. The agonist instead of hCG/LH is usually given on the same day in an amount sufficient to trigger ovulation. A suitable range is 10-1000 µg. Suitable agonists are e.g. buserelin, triptorelin and luporelin.

The exact regimen for administration might depend on the individual response and is finally to be decided by the clinician who treats the subject. For this reason the duration of initial ovarian stimulation with FSH alone as well as the duration of combined treatment with FSH/GnRH antagonist treatment may vary. FSH treatment usually starts at menses day 1, 2 or 3. Ovarian stimulation with FSH alone may be continued up to 5 days in an amount of e.g. 150-225 IU. FSH is administered preferably as a recombinant protein. Treatment with GnRH antagonist may be started at the first day of FSH, but preferably such treatment starts at FSH treatment day 4 or 5. The GnRH antagonist is administered in the previously determined amount according to the invention in combination with FSH in amounts between 50 - 600 IU, preferably between 100 - 300 IU. GnRH antagonist treatment may last 2 - 14

days i.e. up to the moment whereupon the patient is treated with exogenous LH/hCG or a GnRH or GnRH agonist for ovulation induction.

According to another aspect of the invention ganirelix in an amount according to Formula I is used for the manufacture of a medicament to prevent
5 a premature LH surge in women undergoing controlled ovarian hyperstimulation.

The pharmaceutical preparations for use according to the invention can be prepared in accordance with standard techniques such as for example are
10 described in the standard reference, Gennaro et al. (Ed.), Remington's Pharmaceutical Sciences, (18th ed. Mack Publishing Company, 1990, e.g. Part 8: Pharmaceutical Preparations And Their Manufacture). For the purpose of making the pharmaceutical preparations according to the invention, the active substance is mixed with or dissolved in a pharmaceutical acceptable carrier.

15 Any conventional pharmaceutical carrier that does not interfere with performance of the active ingredient can be used in the preparations according to the present invention. Formulations may contain as common excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated
20 naphtalenes and the like.

The pharmaceutical preparation of the antagonist may be administered parenterally. Preferably it is administered subcutaneously, particularly in the form of liquid solutions or suspensions. A typical formulation is a solution containing, in addition to the active substance in an amount as indicated
25 above, glacial acetic acid, mannitol, and water adjusted to pH 5 with sodium hydroxide and / or hydrochloric acid. Optionally preservations such as e.g. methyl- and propylparaben or benzylalcohol can be added. The solutions can be packaged e.g. in glass vials, cartridges or in syringes.

30 In a further aspect of the invention there is provided a cartridge containing a sterile liquid formulation of ganirelix. As used herein a cartridge means a closed container, such as an ampoule, a vial, a bottle or a bag comprising an amount of GnRH antagonist so as to administer accurately and preferably repeatedly to a patient a dosage of GnRH antagonist according to Formula I.

Thus, a cartridge may contain an amount of the liquid antagonist formulation corresponding to one or more therapeutic dosages of the antagonist. Preferably these dosages are to be applied in a single regimen. Preferably the cartridges contain an amount of GnRH antagonist sufficient for
5 5 administrations. The cartridges are preferably used in combination with a device making it possible to deliver adjustable dosages needed in the regimen.

In another aspect of the invention there is provided a device for administration comprising a cartridge containing a sterile liquid formulation according to the invention. A preferred device for administration is a pen-type
10 injector, which comprise means for easy adjustment of the amount of a formulation that is to be injected. Such pen type injectors are known per se, such as for instance the well known B-D Pen (a trademark of Becton Dickinson and Company), an insulin-injection system.

Adjustable cartridges according to the invention have the advantage of
15 accurate self-administration thereby increasing the convenience for the patients.

In yet another aspect of the invention there is provided a kit for use in controlled ovarian hyperstimulation in female patients. Such a kit comprises a
20 GnRH antagonist in a dosage form and quantity so as to accurately administer to a patient in an amount according to Formula I, in a frequency effective to prevent a premature LH surge. In addition the kit comprises FSH in a dosage form and quantity suitable for administering in an amount and frequency effective to stimulate growth of follicles. Optionally the kit may comprise also
25 hCG/LH or GnRH agonists in a dosage form and quantity suitable for administering in an amount and frequency effective to induce ovulation. The GnRH antagonist preferably is packaged in a cartridge. This cartridge preferably is to be used in combination with a device for administration such as a pen type injector allowing an adjustable and accurate administration of
30 GnRH antagonist. Thus, the kit might also comprise a pen type injector system.

The invention is further explained by reference to the following Examples.

Legends to the Figures

Figure 1: LH levels were measured at the start (just before the first injection of ganirelix) and end of ganirelix treatment. The graph shows the pregnancies in relation to the various levels. LH levels are indicated in IU/L.

Figure 2: Area under the curve of ganirelix versus body weight of subjects in three pharmacokinetic studies. Circles mean protocol A; triangles mean protocol B and squares mean protocol C.

10

Figure 3: Chance of pregnancy versus body weight; results from Phase III efficacy study. Dots in the top of the graph correspond to pregnant subjects (100%), while for subjects not pregnant (0%) these dots are displayed at the bottom of the graph. The spline function (chance of pregnancy vs body weight) is the resulting curve of these observations.

15

Examples

Example 1

LH serum levels versus pregnancy

Recombinant FSH (recFSH) treatment was started on day 2 or 3 of the menstrual cycle by a once daily SC injection. Just prior to the first injection of recFSH an hCG test was performed to exclude pregnancy, a blood sample for hormone analysis was taken and an ultrasonography (USS) was performed. During recFSH treatment day 1 through 5, the daily dose of recFSH was fixed to 150 international units (IU). On day 6 of recFSH treatment ganirelix treatment was started by daily SC administration until and including the day before the day of hCG.

During ganirelix treatment, the dose of recFSH was adjusted depending on the individual ovarian response as assessed by USS. From the first day of ganirelix i.e. from recFSH treatment day 6 onwards up to and including the day of hCG, a blood sample for hormone analysis was taken prior to drug administration. And an USS was performed, at least every two days.

LH levels were assessed by a standard LH specific assay at the Central Laboratory of the Analytisch Biochemisch Laboratorium (Assen, The Netherlands). From the data on LH levels, a plot was constructed in order to investigate the possible role of LH on pregnancy.

LH levels were measured at the start (just before the first injection of ganirelix) and end of ganirelix treatment. Figure 1 shows the pregnancies in relation to the various levels.

Clearly, from this graph, no relationship between LH serum levels and pregnancy outcome was found.

Example 2

Body Weight versus pregnancy

For the body weight parameter the treated groups of example 1 were divided into categories of a 10 kg range and the pregnancy rates found for these separate categories were investigated. The results are indicated in Table 1

Weight (kg)	Pregnancy rate
<50	9%
50-60	16%
60-70	22%
70-80	22%
>=80	22%

Table 1: Relationship between pregnancy and body weight

From this table a relationship between the parameter body weight and
5 clinical outcome (i.e. pregnancy) was observed.

Example 3

Body weight vs AUC

Several pharmacokinetic studies were carried out with ganirelix. Protocol
10 A: an open-label two-way crossover study to assess the absolute bioavailability
of 0.25 mg ganirelix after single injection. Protocol B: an open-label
randomized, multiple dose parallel-design study to assess the dose-
proportionality and the pharmacokinetic properties of ganirelix (0.125 , 0.25
and 0.5 mg) after repeated subcutaneous administration. Protocol C: an open,
15 randomized, two-way crossover study to establish the local tolerance and
bioavailability of ganirelix after multiple subcutaneous administration (2 mg).

In all these trials A, B and C, blood samples were taken at regular intervals
and the amount of ganirelix present in the blood was determined. Plots were
prepared showing the amount of ganirelix as a function of time. This allowed
20 the determination of the AUC. Next, the AUC was related to the body weight of
the subjects. Results are indicated in Figure 2.

A pooled analysis of the three pharmacokinetic studies has demonstrated
that the clearance of ganirelix is positively related to body weight. This is
expressed in a lower area under the curve (AUC) for subjects with a higher
25 body weight (Figure 2). Thus at the same dose level, individuals with a
relatively high body weight will be exposed to lower levels of ganirelix, and
individuals with a low body weight to relatively high levels.

As body weight is related to ganirelix levels it can be expected that body weight influences the clinical outcome.

This hypothesis is supported by the results of a large Phase III efficacy study. At lower body weights a significant decrease in pregnancy rate was observed (see example 1 and Figure 3). These subjects have been exposed to relatively higher levels of ganirelix. The pregnancy rate therefore could be optimized in these individuals by adjustment of the dose, according to their body weights.

Example 4

Dose finding

Pharmaco-statistical models have been set up to describe the influence of body weight on the effectiveness of ganirelix for both the prevention of LH-rises and pregnancy outcome. Spline functions have been applied to give the best and assumptionless mathematical description of the available data. Using these models optimal doses with respect to the prevention of LH-rises and pregnancy have been determined for different body weights.

Weight (kg)	Optimal dose (µg)
<50	<128
50-55	128
55-60	158
60-65	185
65-70	211
70-75	238
75-80	264
>=80	>264

Table 2: Relationship between body weight and optimal dose

20

Results are indicated in Table 2. Linear regression shows that these dosages can be given by the formula: $(5.5 \cdot BW - 166) \pm 7\%$ wherein BW is the body weight in kg.

Claims

- 5 1. In the treatment of female patients undergoing controlled ovarian hyperstimulation comprising administration of exogenous FSH and a GnRH antagonist, the improvement comprising administering said antagonist in an amount depending on the body weight of the patient wherein the relationship between body weight (BW in kg) and GnRH antagonist dosage (in micrograms) is defined by the Formula:
10 $(5.5 \cdot BW - 166) \pm 7\%$ (Formula I).
2. Treatment according to claim 1 wherein said GnRH antagonist is ganirelix.
3. A cartridge containing a sterile liquid GnRH antagonist containing formulation in an amount so as to accurately administer to a patient an
15 amount according to Formula 1 of claim 1 or 2.
4. The cartridge of claim 3 wherein the GnRH antagonist is ganirelix.
5. A device for administration of an adjustable sterile liquid GnRH antagonist comprising a cartridge according to claim 3 or 4.
6. Use of GnRH antagonist for the manufacture of a medicament to
20 prevent a premature LH surge in female patients undergoing controlled ovarian hyperstimulation, the method of controlling ovarian hyperstimulation comprising administering to the patient a GnRH antagonist in an amount depending on the body weight of the patient wherein the relationship between body weight (BW in kg) and GnRH
25 antagonist dosage (in micrograms) is defined by the Formula:
 $(5.5 \cdot BW - 166) \pm 7\%$.
7. Use of GnRH antagonist according to claim 6 wherein said GnRH antagonist is ganirelix.
8. A kit for use in controlled ovarian hyperstimulation in female patients
30 comprising a GnRH antagonist in a dosage form and quantity so as to administer accurately in an amount according to Formula I of claim 1 and a frequency effective to prevent a premature LH surge; FSH in a dosage form and quantity so as to administer in an amount and frequency effective to stimulate growth of follicles; and LH/hCG or a

GnRH agonist in an dosage form and quantity so as to administer in an amount and frequency effective to induce ovulation.

9. Kit according to claim 8 wherein the antagonist is ganirelix.
10. Kit according to claims 8 or 9 wherein the antagonist is packaged in a cartridge according to claim 4.
11. Kit according to claims 9-10 comprising a device for administration of an adjustable sterile liquid amount of the antagonist.

Figure 1




Figure 2





Figure 3



INTERNATIONAL SEARCH REPORT

Interr. Application No

PCT/EP 00/05643

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/09 A61P5/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 58657 A (ORLEMANS EVERARDUS OTTO MARIA ;AKZO NOBEL NV (NL); COELINGH BENNIN) 30 December 1998 (1998-12-30) cited in the application the whole document --- -/--	1-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 August 2000

Date of mailing of the international search report

06/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stein, A

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 00/05643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>THE GANIRELIX DOSE-FINDING STUDY GROUP: "A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)" HUMAN REPRODUCTION, vol. 13, no. 11, 1998, pages 3023-3031, XP000876538 the whole document</p>	1-11
A	<p>WO 98 55470 A (CHU LIN ;GOULET MARK (US); MERCK & CO INC (US); WALSH THOMAS F (US) 10 December 1998 (1998-12-10) page 2, line 17 - line 33 page 3, line 32 -page 4, line 2 page 40, line 31 -page 41, line 33</p>	1-11
A	<p>PAULSON R J ET AL: "Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience." JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, (1994 JAN) 11 (1) 28-32., XP000876515 the whole document</p>	1-11
P,X	<p>OBERYÉ J ET AL: "Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections" HUMAN REPRODUCTION, vol. 15, no. 2, February 2000 (2000-02), pages 245-249, XP000876537 the whole document</p>	2-5,10, 11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05643

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9858657 A	30-12-1998	AU 8727798 A EP 0994718 A	04-01-1999 26-04-2000
WO 9855470 A	10-12-1998	AU 7806898 A EP 0986550 A US 5981550 A	21-12-1998 22-03-2000 09-11-1999